PALATIN TECHNOLOGIES INC
Close on Oct 19, 2026
- Market cap
- $23.46M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Sep 30, 2024 | Oct 1, 2024 | Before market open | – | $-0.51 | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-0.53 | – |
| Q2 FY2024 Ended Jan 31, 2024 | Feb 15, 2024 | Before market open | $2.00M | $-0.56 | – |
| Q4 FY2023 Ended Jun 30, 2023 | Sep 28, 2023 | Before market open | $1.76M | $-0.91 | – |
| Q3 FY2023 Ended Mar 31, 2023 | May 16, 2023 | Before market open | $1.20M | $-0.63 | – |
| Q2 FY2023 Ended Dec 31, 2022 | Feb 15, 2023 | Before market open | $1.03M | $-0.13 | – |
| Q4 FY2022 Ended Jun 30, 2022 | Sep 22, 2022 | Before market open | $770.74K | $-1.34 | – |
| Q3 FY2022 Ended Mar 31, 2022 | May 17, 2022 | Before market open | $216.10K | $-0.03 | – |
| Q2 FY2022 Ended Dec 31, 2021 | Feb 15, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Sep 30, 2021 | Nov 15, 2021 | Before market open | – | – | – |
| Q4 FY2021 Ended Jun 30, 2021 | Sep 29, 2021 | Before market open | – | – | – |
| Q3 FY2021 Ended Mar 31, 2021 | May 17, 2021 | Before market open | – | – | – |
Press releases
Announcements Palatin Technologies filed with the SEC
to Begin Trading on Nasdaq Stock Exchange
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal
Other events · EX-99.1 to Form 8-K
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Palatin Announces 1-for-50 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Palatin Technologies Announces Transition to OTC Pink Following
Material agreement · Listing notice · Other events · EX-99.1 to Form 8-K
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Material agreement · Listing notice · Other events · EX-99.2 to Form 8-K
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of
Listing notice · Other events · EX-99.1 to Form 8-K
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis
Other events · EX-99.1 to Form 8-K
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with
Other events · EX-99.2 to Form 8-K
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Palatin Announces Exercise of Warrants for Approximately
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Results of operations · EX-99.1 to Form 8-K
Palatin Receives Notice of Non-Compliance from NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results,
Results of operations · EX-99.1 to Form 8-K
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
Palatin Announces $10 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Palatin Announces Closing of $10 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Palatin Completes Sale of Vyleesi ® to
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
PTN - Palatin Announces $5 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Palatin Announces Preliminary Quarter Ended
Results of operations · Other events · EX-99.1 to Form 8-K
Palatin Receives Notice of Non-Compliance from NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Palatin to Present at the H.C. Wainwright
Other events · EX-99.1 to Form 8-K
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
Other events · EX-99.1 to Form 8-K
Palatin Provides Update on VYLEESI® Collaborations
Other events · EX-99.1 to Form 8-K
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
Other events · EX-99.1 to Form 8-K
Canaccord Genuity’s 43 rd Annual Growth Conference
Other events · EX-99.1 to Form 8-K
Palatin Announces Preliminary Fourth Quarter Fiscal 2023
Other events · EX-99.1 to Form 8-K
Palatin Presents Preclinical Diabetic Nephropathy Data at the
Other events · EX-99.1 to Form 8-K
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Palatin to Report Third Quarter Fiscal Year 2023 Results;
Other events · EX-99.1 to Form 8-K
Palatin Invites Investors to Listen to Replay of the
Other events · EX-99.1 to Form 8-K
Palatin Presents PL8177 Ulcerative Colitis Data at
Other events · EX-99.2 to Form 8-K